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13.1 General Introduction 
Cellular materials are amenable to NMR spectroscopic investigation, and can reveal a wealth of 
information relating to intracellular and extracellular metabolome composition via metabolic 
profiling. In this chapter, we consider aspects of the sampling and analysis of biological materials 
from sources of varying structural complexity including cells, tissues, and whole organisms. On 
account of our own expertise, we focus predominantly on animal samples; specific aspects relating 
to plants are well covered in other texts.1-3 While whole organisms and tissue commonly provide an 
ensemble of cell types, cultured cells can offer a unique perspective on various individual cell types 
and their corresponding suite of specialised functions. Cells in culture can also be analysed via 
their metabolic footprint in the culture media, offering a complementary set of measurements to 
those obtained that describe the intracellular metabolome. In this chapter, we also consider the 
sampling and analysis of specialised body fluids that can provide specific organ-, function-, and 
system-level information, and those that have been explored in metabolic profiling studies to date 
are discussed (specifically faeces, cerebrospinal fluid, milk, seminal fluid, and bile). In doing so, we 
highlight the need to accommodate their unique physical and biochemical properties (e.g. 
composition, dynamism, etc.) in order to generate high-quality NMR spectra, and direct the reader 
to exemplars in the scientific literature. 
 
13.2  Sampling, Extraction and Analysis of Cellular Material 
 
13.2.1  Introduction  
Metabolomics is focused on characterising biochemical phenotypic traits and the variation these 
display over time, space and between individual entities. Therefore, the main aim of biosampling 
for metabolomics applications is to halt (quench) cellular metabolism as quickly as possible, in a 
way that keeps the chemical milieu of the sample intact and sufficiently representative. Metabolite 
pools (e.g. nucleotides) can turn over rapidly, with some responding at the (sub)second-timescale4. 
There is consensus that rapid quenching of metabolic processes is critical to ensure subsequent 
metabolic profiles best reflect the sample at the chosen sampling timepoint. Consequently, 
collection of samples for the purposes of metabolic profiling analysis typically involves methods 
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that are aimed at minimising the effects of the sampling process itself (e.g. continuation of 
metabolism on the bench). Another major consideration is the sufficient isolation of the sample 
from its immediate environment, which is particularly important when the composition of the 
extracellular matrix is dominated by one or more high concentration components, something that is 
common in cell or bacterial culture (e.g. high glucose concentration and low intra- to extracellular 
volume ratio). Failure to do so (e.g. with insufficient washing) can affect the quality and validity of 
resulting NMR spectra, with minor metabolites signals in multiple regions difficult/impossible to 
deconvolute from those of more abundant species. 
Clearly, there are numerous factors that need be considered prior to sampling (e.g. growth 
conditions such as culture medium/serum used); these play an important role for the metabolite 
profiles of bacterial or tissue culture samples, and thus should be controlled for within a set of 
experiments. 5-7 It is also known that cellular metabolite concentrations depend on cell density and 
confluence of the cells. 8  The experimental system itself places demands on the analytical 
workflow; cell type and whether cells are adherent or cultured in suspension played an important 
role in determining which preparative methods maybe the most suitable. Other variables are cell 
wash cycles, solvent selection, addition of chelation or buffering compounds, use of filtration for 
suspension culture, and use of scraping devices for sampling of monolayer cultures.  
 
Note: The analysis of intact tissues by magic angle spinning (MAS) NMR spectroscopy provides a 
unique approach to characterisation of various aspects of composition, cellular metabolism, 
compartmentation, and provides valuable insight on the tissue as an ensemble. Such analyses are 
also particularly well-suited to the provision of rapid histopathological information based on 
metabolic signatures; NMR spectroscopic platforms are now being introduced into surgical settings 
to augment existing assessment techniques and are elsewhere in this book. 
 
The preparation of NMR-ready samples of whole organisms, intact tissue specimens, and cell 
culture materials follow the same pipeline or workflow. This can largely be divided into three main 
sets of tasks that precede spectroscopic analysis (see Figure 13.1): 
1. Sampling and separation of the cellular material from its surrounding environment 
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2. Adequate quenching/cessation of metabolic processes to best preserve the metabolome 
status at the time of sampling 
3. Extraction of metabolites according to target criteria for metabolome coverage 
 
[Figure 13.1 near here] 
 
Depending on the specific workflow and sample type, these steps may be integrated, and it is 
therefore useful to consider them in a holistic manner when approaching an analysis. 
 
13.2.2  Sampling Cellular Material 
At present, NMR spectroscopic methods for the routine analysis of single cells is not feasible in the 
context of metabolic profiling studies, and therefore material from multiple cells are combined to 
provide sufficient sample. The relative insensitivity of NMR spectroscopy compared with other 
spectroscopic and spectrometric techniques is well known, and while the analysis of very dilute 
samples is possible by the acquisition of a large number of transients, this obviously reduces 
sample throughput and increases per-sample resource cost. As with other biofluids described in 
this book, high-throughput analysis of samples with natural-abundance isotopes is restricted to 1H 
for profiling applications, additional experiments using 13C, 15N and 19F are possible and typically 
used for metabolite identification. Despite the requirement for sufficient material to overcome the 
inherent instrumental insensitivity, general sample requirements are not prohibitive for most 
applications; for tissues samples, a typical sample of around 100mg is ideal, with a lower limit of 
around 20mg; for mammalian cells in culture, adequate material for both intracellular extracts and 
extracellular media can be obtained from confluent T75-size flasks, although six-well plate cultures 
can be used (target of 5x105 - 5x106 cells), and some researchers prefer using larger cultures 
where feasible (particularly for microbial culture). 
 
Notwithstanding the need to select a source that can provide sufficient and representative material 
at a given sampling time, the analyst must first decide on the type of sample that is most 
appropriate.  Whole-organism analysis is commonly employed in areas of research where 
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subsampling would be prohibitively time-consuming, result in dramatic and confounding changes 
to the samples, or where the organism is small or structurally simple.9-12 Ideally, the organism must 
be taken from its environment (natural or laboratory), and metabolism should be stopped before it 
responds to the sampling procedure to exclude confounding variation. Similarly, the cells of the 
organism should remain intact during this procedure as not to interfere with subsequent extraction 
step(s), back at the laboratory bench. Some sampling locations may present specific challenges 
for adequate sampling that are not present in the laboratory (where all instrumentation and 
facilities are near at hand) or in surgical/clinical scenarios (where the sample source can 
commonly be requested to attend a particular site); such sampling locations may be difficult to 
access, or associated with physical factors that limit what is practicable (e.g. weather, travel time to 
laboratory). For these reasons, this approach to sampling is employed commonly in the field of 
environmental metabolomics research, and measures put in place to ensure sufficiently rapid and 
effective isolation, storage and transport. 
 
Whole organism sampling in a laboratory environment may also include cells in culture (i.e. single-
celled organisms), which require isolation from their growth media and transfer from the culture 
vessel for further processing and analysis. For those suspended in culture media, this can be 
easily achieved by filtration or centrifugation, which separates the supernatant, and can be 
efficiently integrated into the laboratory workflow; using a filtration and syringe method, Bort et al. 
recently demonstrated reduced quenching and extraction time for suspension culture.13 Adherent 
cells in culture present an obvious additional requirement in the sampling procedure in that they 
require detachment from the culture vessel surface as well as separation from the growth media. 
This is achieved by gentle scraping with a plastic implement across the vessel surface, which 
dislodges the cells and allows them to be removed; this step is typically integrated with quenching 
solvent addition (see below). Removal and/or sampling of culture media can be achieved by using 
simple suction apparatus, leaving the adhered cells attached to the culture flask. If required for 
subsequent analysis, media is typically centrifuged immediately after sampling to remove 
particulate matter and frozen for storage using by placement on dry ice or into a liquid nitrogen 
bath. Optionally, and dependent on the constraints of the experimental design/aim, samples may 
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be washed with salt buffer prior to quenching to remove residual media components, and thus 
reduce the potential conflation of intracellular and extracellular metabolic signatures.  Ice-cold (4 C) 
saline / PBS/ Ringer’s buffer/ methanol are often used as wash solution.  While removal of the 
growth media may reduce the influence of the sample matrix on the derived profiles of harvested 
cells, there is the potential for intracellular metabolite pools to be altered during this process, due 
to the additional time required to perform the procedure, as a consequence of rapid cellular 
responses to altered culture environment or due to leakage. Trypsinisation is an alternative method 
for harvesting cell samples from adherent culture, and the effect of trypsin as an agent to detach 
adherent cells from their growth container has previously been assessed in relation to the 
metabolome using various platforms.14-16 In brief, there are several limitations to this approach: i) it 
requires the addition of serum-containing media and introduces the requirement for further wash 
steps that may confound analysis of the metabolome profile; ii) the additional time required (~3 
mins) for the samples to detach while in altered media conditions may allow confounding metabolic 
changes to occur; iii) the application may directly cause metabolic responses.  
 
In the majority of cases, the vasculature in and around excised tissue samples will contain blood. 
In order to minimise the influence of conflating the blood metabolome profile with that of the target 
sample tissue, it is common to ensure that tissues are washed. Allwood et al. (2012) suggest that 
washing with cold saline solution will remove extra- and intra-tissue blood prior to freezing and 
prevent cross-contamination of tissue types.17 To avoid significant post-operative / post collection 
changes in the tissue metabolome, it is recommended that samples be cooled with a cryogen as 
soon as is practicable; the reduction of the sample temperature (e.g. -196 C for liq. N2) results in 
cessation of metabolic processes within a few seconds. Rapid freezing of tissues can also be 
routinely achieved by full immersion in a cryogen, typically liquid nitrogen (N2 (liq.) in a process 
known as ‘snap-freezing’.  Haukaas et al. (2016) examined the effect of freezing delay on 
metabolic profiles of excised tumor tissue, indicating that delay in snap freezing samples lead to 
NMR-observable changes, and suggesting a delays to freezing be minimized (less than 30 mins). 
18 While keeping temperatures as low as possible whenever feasible, this is not always possible, 
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although it would appear there is consensus that samples should be maintained below −20 C 
during sample harvesting.19 
 
5.2.3 Quenching Metabolism 
The immediate cryogenic cooling of snap-freezing has clear benefits for sampling of culture media 
and tissues. It is therefore common for quenching steps to be directly integrated in the sampling 
procedure. For adherent cells, a quenching solution is applied (cold methanol/ cold aqueous 
methanol is often used) as soon as the wash solution/ media has been removed and cells are 
scraped off whilst remaining in contact with the quenching solution.   
 
The problem of quenching is arguably bigger in microbial systems. As most microbes grow in broth 
or media of some sort, metabolite carry-over from these media is a potential issue - quenching also 
requires the separation of the intact cells from the growth medium. The pool sizes of the 
intracellular metabolites are at a maximum comparable to those of the extracellular matrix or 
medium (only for eukaryotes like yeast). For all bacteria, the absolute abundance of metabolite 
outside the cells by far outweigh the abundance inside the cells.  Methanol quenching, during 
which cells are first rapidly cooled in -40 C methanol has been proposed 20 and this method with 
minor modifications became the de facto standard for some time.21 Several studies reported 
cellular leakage induced by methanol quenching, particularly for Gram-negative bacteria.22-24 Rapid 
filtration, in which cells are transferred onto a filter paper and then put directly into the extraction 
solvent23 have been suggested as an alternative, but is relatively slow (~30s) in comparison to 
direct addition; this is particularly relevant in light of the high metabolic turn-over rates in 
exponentially growing bacteria. Another alternative approach in which cells are grown on a filter 
paper on top of an agar plate provides the potential for rapid quenching, but is limited by the 
fundamental alteration this setup makes to the physiological state of the bacteria (c.f. liquid 
culture).25  Quenching, in the field of microbial metabolomics therefore remains an unresolved 
problem, although established protocols exist for some Gram-positive organisms.26,27 More 
generally, membrane integrity during the quenching process should be considered, particularly if 
the supernatant from the quenching process is subsequently excluded from the analysis (e.g. 
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suspension culture); bacterial cells and mammalian cells may differ in their susceptibilities to 
membrane/ intracellular metabolite leakage in organic solvent due to the presence of cell wall in 
bacterial cells. For example, Canelas et al. (2008) demonstrated that applying pure methanol as 
quenching solution at below -40 C can prevent metabolite leakage in yeast cells.28 
 
13.2.4. Extraction of Intracellular Metabolites 
Cellular materials require preparation to facilitate the acquisition of solution-state NMR spectra 
spectra that are useful for metabolic profiling. In order to provide representative profile data, there 
is often a need to extract samples to separate metabolites and enable the acquisition of high-
quality spectra that do not suffer from interference from the original sample matrix. There are a 
variety of physical and chemical processes that can be used for extraction, but care must be taken 
to select a method that is appropriate for the target criteria; extraction of samples is accompanied 
with variable metabolite selectivity, loss, and potential for metabolite alteration. Additionally, these 
methods may be used in combination to select or maximise metabolite recovery. In short: the 
choice of extraction method(s) is important as it impacts on the subset of metabolites that are 
recovered from a sample – and therefore potentially observable – in subsequent NMR 
spectroscopic analyses. Extraction of sampled tissues enables analysis of solution-state samples, 
which conveys several advantages at the expense of ensemble information analysis, and 
increased preparative effort (c.f. MAS NMR spectroscopy). In particular, analysis of tissue extracts 
enables broad separation of metabolites according to physicochemical properties (typically 
according to lipophilicity) and permits optimised analysis of these metabolome subsets. Analysis of 
multiple extract types (e.g. aqueous and organic fractions) can collectively improve the overall 
metabolite coverage available, and facilitate the use of optimised methods in subsequent profiling 
by NMR spectroscopy.   
 
13.2.4.1 Physical Extraction 
In order to achieve an efficient and rapid recovery of metabolites during extraction, pre-treatment 
by mechanical disruption can be used. This results in bulk sample homogenisation and cellular 
fracture, releasing intracellular metabolites, permitting partitioning into extraction solvents and 
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subsequent separation from the insoluble sample matrix components.  The simplest method of 
achieving physical sample disruption is for frozen tissues to undergo manual grinding using a 
handheld/automated pestle and mortar29 or mincer.  Alternative methods are the use of a 
homogenizer, ball mill30 or other type of bead beater11 31. Other methods for aiding cellular 
disruption includs cycles of freeze-thaw, 32-34 ultrasonication35 or acoustic cavitation33.  
 
13.2.4.2 Chemical Extraction 
Two main types of chemical extraction are commonly used in the preparation of cellular material 
for NMR spectroscopic analysis, discussed in turn below. (1) Perchloric acid extraction involves the 
addition of ice-cold perchloric acid (PCA; HClO4) to harvested cells, followed by vortex-mixing to 
yield a precipitate of macromolecules including proteins and lipids, which can be separated by high 
speed centrifugation. 36  The acidic supernatant is removed and neutralised by titration with 
potassium hydroxide, yielding potassium perchlorate (KClO4), which can be removed as a 
precipitate by further centrifugation on account of its low solubility. The neutralised supernatant is 
then either prepared directly or lyophilised and stored for subsequent reconstitution in NMR buffer 
for analysis. The macromolecular pellet can be neutralised and further extracted using organic 
solvents to yield a sample containing the precipitated lipids, which are amenable to NMR analysis. 
PCA extraction is limited by several factors including the potential for metabolite oxidation, the 
necessity of substantial pH change that may hydrolyse acid-labile species and the need to 
neutralise the supernatant/precipitate. (2) Dual-phase solvent extraction involves the sequential 
addition of aliquots of ice-cold methanol:water and chloroform to harvested cells, followed by 
vortex-mixing and then placement on ice to precipitate proteins (note: glass tubes should be used 
to prevent contamination from sample tube components).37 Separation of phases is achieved by 
high-speed centrifugation, yielding a biphasic sample (upper methanolic aqueous phase; lower 
organic chloroform phase) with the insoluble precipitate at the interface. Both phases can be 
carefully removed to separate vials and dried by lyophilisation, speedvac, or under inert gas, prior 
to reconstitution in a suitable solvent for NMR spectroscopic analysis. Recovery can be improved 
by multiple extractions of the residual precipitate, and pooling of the separated fractions. The 
precipitate can be used for protein estimation if required (e.g. by use of the bicinchoninic acid 
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(BCA) protein assay38). This method does require several steps, but has the advantage of 
efficiently generating a complementary pair of aqueous and organic samples that can be analysed 
separately. Individual researchers have explored multiple variations of these two main extraction 
techniques, with specific steps of modifications able to preferentially select or preserve metabolites 
of interest.39  For suspended cells, Sellick et al. (2011) have provided a very detailed protocol for 
preparation compatible with multiple analytical platforms.40 Additionally, a variety of other 
solvents/compositions/methods have been used for the extraction of cellular metabolites; some 
key exemplars are summarised in Table 1.  
 
[Table 13.1 near here] 
Requires references: 13,14,20,35,37,39-53 
 
Irrespective of the protocol used, we stress here that the need to work quickly and ensure that 
washing is conducted in a manner that does not disrupt the integrity of the cellular material 
composition is paramount. Additionally, we suggest that researchers record in detail the time 
between the excision of material and subsequent freezing, run order, and autosampler residence 
time, to allow post-hoc assessment of any time-related changes to the observed metabolic profile 
associated with this step (and potential to adjust analyses accordingly). 54 
 
While we have considered the needs of NMR spectroscopy, it is common practice for multiple 
analytical platforms to be used in parallel, which places additional – and potentially conflicting – 
requirements on the methods used for sampling/harvesting/preparation of biological materials.  
To this end, Beltran et al. (2012) addressed the issue of the compatibility of sample preparation in 
NMR spectroscopy and LCMS. 55 The authors highlighting the complications in LCMS analyses 
that can arise from the use of deuterated solvents, and the influence of pH on the ionization of 
analytes in the MS source as a consequence of extraction solvent choice (e.g. acid). They 
evaluated 12 different solvent extraction protocols / conditions for the analysis of liver tissue. In 
summary, they found that hydrogen/deuterium exchange did not affect LCMS profiles, and solvent 
choice dominated the extraction efficiency of the protocols over other factors (e.g. temperature). 
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They concluded that where NMR spectroscopic and LCMS analyses of the same sample are 
anticipated, the use of methanolic aqueous extractions are preferred. 
 
13.2.5  NMR Spectroscopy of Cellular Materials 
Samples are typically prepared by dilution or in buffer containing an internal reference at a 
concentration that is in the same range (or greater) than that expected for metabolites present, and 
used as both a chemical shift reference as well as for metabolite quantification/estimation. TSP-d4 
(3-(trimethylsilyl)propionic-2,2,3,3-d4 acid or DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) are 
most commonly used for aqueous samples. For samples with a considerable protein/lipoprotein 
content where the internal standard chemical shift and peakshape may be affected due to protein 
binding, it is common for spectra to be referenced to the anomeric proton resonance of -glucose 
(if present) as it has a chemical shift that is largely unaffected by the presence of these species; 
glucose is commonly abundant in various media.56 The synthetic compound 4,4-Dimethyl-4-
silapentane-1-ammonium trifluoroacetate (DSA) has been suggested as an alternative, but has not 
found widespread use at the time of writing.57 Lyophilised samples are commonly re-dissolved in 
D2O or D2O-based buffer as this minimised the requirement for substantial water suppression 
during NMR acquisition. For aqueous samples, the pH may be adjusted using standard methods 
(typically addition of ~5uL volumes of 1 M HCl or 1M NaOH, or their deuterated equivalents). Cell 
culture media analysis, commonly only requires addition of a deuterated solvent to facilitate 
spectrometer lock, and centrifugation to remove any suspended debris, prior to transfer to the 
analysis vessel. Lipid extracts that have been dried are commonly resuspended in CDCl3 
containing tetramethylsilane (TMS) as an internal chemical shift reference. 
 
Prepared extracted cellular materials are amenable to the whole gamut of NMR experiments, as 
detailed elsewhere in this book, but may present instrumental challenges when at low 
concentration (e.g. extracts of limited tissue mass or from a small number of cells). In the context 
of metabolic profiling, the most commonly-used experiments are those that produce a one-
dimensional profile spectrum either directly (1D) or from the calculation of a projection/skyline 
spectrum (e.g. 1D JRES). Specific challenges for extracted cellular materials include the need to 
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reduce the influence of the solvent signal(s), and also broad resonances arising from 
macromolecular components. These are discussed in turn below. For samples comprised of, or 
prepared in, aqueous media, there is a need to incorporate water suppression into 1H NMR pulse 
sequences; failure to do so results in unusable spectra on account of the very large signal for this 
resonance. As mentioned above, one route to minimising this is to lyophilise the sample and 
reconstitute in D2O or D2O-based buffer, although this results in the loss of highly volatile 
compounds such as acetone.  The most common approach to water resonance suppression, a 
presaturation pulse with a narrow bandwidth is applied during the recycle delay (typically 3-4s), 
centred at the water resonance (~4.7 ppm relative to TSP-d4 at 0.0 ppm in aqueous samples), 
although other techniques such as WET sequence58 or WATERGATE excitation sculpting can be 
implemented59,60. Similarly, presence of other protonated solvents in sample will present the need 
to employ solvent suppression at each of the resonances that result. 1D pulse sequences based 
on an increment of the nuclear Overhauser effect experiment that improve the efficiency of the 
water suppression through volume selection (informally referred to as a NOESYpresat 
experiment)61 are commonplace. 
 
NMR spectroscopic analysis of extracts that contain macromolecular components (e.g. proteins) at 
an appreciable concentration (e.g. cell culture media containing fetal calf serum or extracts where 
adequate removal has not been possible), yield spectra containing broad peaks that affect wide 
chemical shift regions, which can confound subsequent data analysis. These resonances result 
from the short time taken for T2 spin-spin relaxation to occur in these slow-tumbling 
macromolecules, a phenomenon which can be minimised using spin-echo spectral editing 
techniques; pulse sequences based on the Carr-Purcell-Meiboom-Gill (CPMG sequence) are 
common, with the spin-echo parameters adjusted to provide adequate removal of the unwanted 
signals according to sample type.62 J-resolved spectra are also used routinely, and result in a 
reduced complexity and overlap on account of the removal of coupling constant from the spectral 
projection of the profile.63 As described above, the preparative steps for cell extracts include 
quenching of metabolism and/or removal of proteins and therefore samples are typically stable at 
room temperature for short periods. To reduce the potential for degradation to occur while in the 
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sample vessel, cooled sample holders (e.g. Bruker SampleJet) are recommended, particularly for 
samples that will reside in an instrument autosampler for an extended period.  
 
13.3 Cellular Material Profiling Applications  
NMR-based metabolomics has been shown to be a versatile tool for the study of whole organisms; 
these include metabolic changes associated with bacterial community evolution in various 
contexts,64-66 response to environmental stress, 67,68 microbial classification,69 general bacterial 
physiology, 70,71and others. Multicellular organisms have been well studied, including the 
characterization of biochemical diversity of betaines in earthworms,72 contribution to the taxonomic 
description of cryptic species 73, investigation into the effects of heavy metal pollution on the 
invertebrate communities. 74,75 and heat stress in Drosphila76,77. Blaise and co-workers have 
investigated the utility of NMR-based metabolomics with C. elegans78 79 with other studies focused 
on the metabolic changes associated with ageing and physiology80-82.   
Earthworm sampling provides a useful exemplar with which to illustrate the challenges of in-field 
sampling and subsequent extraction and analysis and will be discussed below. On field trips for 
environmental research, in order to quench metabolism, earthworms are often snap-frozen in liquid 
nitrogen on-site, as this is a relatively portable setup, and provides a balance with adequate 
cessation of metabolism. In the majority of cases and/or for larger samples, on-site subsampling 
would be unfeasible and likely result in considerable metabolic changes. Frozen samples of whole 
organisms are then mechanically ground in liquid nitrogen and subsequently extracted with a 
suitable solvent73. For earthworms, evidence suggests that even these extracts require a further 
‘stabilisation’ step prior to resuspension in aqueous solvents prior to analysis; Liebeke and Bundy 
(2011) found that otherwise chemically-stable metabolites are converted by the residual enzymatic 
activity within the extracts9.  
 
NMR spectroscopy of tissue extract has found widespread use across multiple areas of 
bioscience, notably in the assessment of toxicological responses, In several case, researchers 
have sampled and integrated metabolite profiles obtained from multiple tissues to provide a more 
holistic view; for example, Ling et al. (2014)83 used a combination of 500 MHz 1H NMR spectra 
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(one-dimensional and 2D J-resolved) to generate metabolic profiles of extracted tissues to 
delineate the effect of naphthalene exposure across multiple organs in a mouse model. A 
summary of the resulting multivariate analysis is shown in Figure 13.2. This highlights one key 
aspect of NMR-based metabolome profiles – it is relatively simple to employ a common protocol 
across multiple tissue types, and subsequently generate directly compatible datasets that report on 
metabolites in a consistent manner (see Fig. 13.2). 
 
[Figure 13.2 near here] 
 
Metabolome analysis of mammalian cell cultures is also now routine in many laboratories, with 
particular utility being found in preclinical mechanistic research; the diversity and volume of 
research published cannot easily be summarised, although Penet et al. (2012)84 provide an 
excellent synopsis in relation to the cancer metabolome. Cancer cell lines have arguably received 
the greatest attention on account of the need to improve translational medicines, the diversity of 
cancer subtypes, and the common dysregulation of core metabolic processes (e.g. Warburg effect) 
as a hallmark of cancer. As an example, Cuperlovic-Culf et al. (2011) used NMR-based metabolic 
profiling in combination with RNA expression analysis to delineate the differences in breast cancer 
subtypes in vitro. 85 (Figure 13.3) 
 
 [Figure 13.3 near here] 
 
It is common for parallel analyses of both intracellular extracts and extracellular supernatants to be 
combined to provide an efficient model of metabolite flux including uptake of media components, 
and export of metabolites from the cells. Media can be serially sampled at a relatively frequency, 
and provides an efficient and non-invasive/non-destructive means of monitoring culture conditions, 
particularly changes in high abundance components (e.g. glucose, lactate, amino acids).86 
Adherent cell extracts cannot be serially sampled in the same way, and therefore longitudinal 
sampling require parallel plates/flasks to be maintained, which has additional resource cost; 
increasing the plate well density necessarily reduces the number of cells at harvest, and therefore 
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places a limit on throughput. Advances in isotopic enrichment and DNP may offer a potential route 
towards much higher throughput/lower material requirements; Dumez et al. (2015) have 
demonstrated application of this technique to cell extracts, reporting the acquisition of high-quality 
2D NMR spectra in a fraction the time (see Figure 13.4). 
 
(a) Conventional HMBC spectrum, recorded in 13 h 42 min at 500 MHz with a cryogenic probe, on 
a partially enriched extract (ca. 57 million extracted cells) dissolved in 700 μL D2O. (b) 
Hyperpolarized single-scan spectrum. The cell extract was dissolved in 200 μL of a mixture of 
H2O/D2O/glycerol-d8 (2 : 3 : 5) with 25 mM TEMPOL and polarized for 30 min at 1.2 K and 6.7 T, 
and finally dissolved with 5 mL D2O. A fraction of 700 μL of the hyperpolarized sample was 
injected in a 500 MHz spectrometer equipped with a cryogenic probe where the spectrum was 
recorded in a single scan. (c) Same as (b), but with a natural abundance extract (ca. 113 million 
cells) obtained from the same SKBR3 cell line. 
 
[Figure 13.4 near here] 
 
 
13.4 Other Biofluids 
 
13.4.1  Introduction 
As detailed elsewhere in this book, the most commonly used sample types in metabolic profiling of 
animals are urine and blood (typically serum or plasma preparations); these fluids are convenient 
to collect, and report on metabolic phenotypes at the system-level. A vast array of other distinct, 
and physiologically-specialised biofluids exist, each performing different biological roles, and under 
coordinated regulation within organisms (Fig. 13.5). Importantly, the small-molecule composition of 
each fluid encodes a different set of metabolic information, relating to its source, distribution, 
longevity, function, and a host of other interacting factors. Similar to the analysis of specific types 
of cellular materials discussed earlier in this chapter, the ability to sample and characterise more 
exotic fluids can provide additional windows on cellular, tissue, organ, and systemic function that 
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report more specifically than blood plasma or urine. Furthermore, the parallel profiling of multiple 
specialised fluids can provide a more comprehensive view of the determinants of the overall 
systemic function. As noted by Nicholson et al.  (2012), in most cases, only a small number of 
biofluids or tissues can be readily accessed, with each providing an ‘island of information’; the 
long-term challenge is to develop appropriate methods for systems-level integration of metabolic 
information obtained from individual sample types. 87 
 
[Figure 13.5 near here] 
 
The nature of the NMR spectroscopic analytical platforms used to conduct metabolic profiling 
experiments is such that almost any biofluid is amenable to characterisation in some meaningful 
way. In general, differences in analysis lie in a) the preparative steps used to ensure high-quality 
spectra/data can be obtained (i.e. by limiting the effects of the sample matrix) and b) in the range 
of commonly-observed metabolites. Here, we focus on fluids other than urine and blood that have 
been explored using NMR spectroscopy-based metabolic profiling; we consider in turn 
cerebrospinal fluid, faeces, milk, seminal fluid, synovial fluid and bile – five sample types that are 
either easily or routinely collected in clinical and preclinical study scenarios, and for which NMR-
based spectroscopic analysis for the purposes of metabonomics analysis has been investigated. 
More recondite fluids (e.g. bronchiolar alveolar lavage fluid, amniotic fluid ascites, cervical mucus, 
pus, organ dialysates, tears, etc.), are discussed only briefly as their exploration by metabolic 
profiling is still in its infancy and literature is scarce. 
 
13.4.2  Faeces 
Faeces is the solid waste matter that is passed from the digestive tract, containing undigested 
food, metabolic by-products, mucus, bile, bilirubin, microorganisms and water.88 Due to the direct 
relevance it has to both individual nutritional practices, and interface with the gastrointestinal (GI) 
tract itself, metabolic profiling of faecal samples has been used in a wide variety of research 
related to diet and GI disease.89 Additionally, because the mammalian gut is populated by a 
diverse, and highly dynamic set of microorganisms, that are intricately involved in a number of 
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biological processes (e.g. digestion, co-metabolism, enterohepatic recirculation, and immune 
regulation), metabolic profiles obtained from faecal matter are of particular interest to those wishing 
to understand mammalian-microbial interactions (especially in conjunction with microbiome 
analyses). Faeces can be easily obtained in a non-invasive manner, and can therefore be routinely 
collected in clinical and preclinical settings.  
 
As a bulk excretory material with a strong relationship with food intake, faecal matter can vary 
considerably in composition, and samples may be heterogeneous in nature. Metabolic profiling of 
faecal matter by NMR spectroscopy requires samples to be processed, and several studies of 
have been conducted to establish appropriate methods for sample extraction; approaches using 
very limited sample preparation have been attempted; Bezabeh et al. (2009) reported that 
application of 1H NMR spectroscopy to unextracted / raw faecal material, resulted in spectra with 
relatively poor resolution.90 In addition to the aqueous- and lipid- soluble components of faecal 
matter typically contains (semi-digested) dietary fibre as a consequence of ingesting plant-based 
material. Preparation of faecal samples typically includes the following steps to generate extracts 
that are both amenable to high-resolution NMR spectroscopic analysis and representative of their 
source material: i) homogenisation of the sample to improve representativeness of individual 
aliquots; ii) physical disruption of sample components using a tissuelyser to release 
trapped/partitioned metabolites; iii) removal of particulate matter by filtration or centrifugation to 
ensure high-quality spectra can be obtained; iv) selection of an extraction solvent appropriate; v) 
sufficient repetition of the extraction procedure. Methods for faecal sample preparation in metabolic 
profiling applications that address these considerations (including specific considerations for NMR 
spectroscopic analysis) have recently been reviewed in detail by Deda et al. (2015).91  
 
The complexity of this sample matrix has led to multiple strategies for obtaining adequately 
prepared samples; citing limitation of previous studies that did not fully account for the effects of 
the sample:solvent ratio or the resultant pH, Wu et al. (2010) compared different bulk sample 
preparation techniques (ultrasonic homogenisation and tissuelyser bead disruption), alongside 
optimising sample extraction parameters. 92 The authors’ recommendation that for optimal spectral 
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signal-to-noise ratio, pH-related chemical shift consistency, and appropriateness for high-
throughput / large scale analyses, that homogenisation be conducted using a tissuelyser, and the 
sample diluted in buffer to a final faeces concentration of 0.1 mg*ul-1 (weight of faeces-to-buffer 
volume ratio; Wf:Vb of 1:10). The authors noted that manual ultrasonication of samples can provide 
a similar extraction where a tissuelyser is not available, and that their use in combination also 
yields largely similar spectral profiles. Lamichhane et al. (2015) revisited this aspect of faecal 
sample to provide specific advice for the preparation of human samples.93 Citing the clear inter-
species differences in faecal metabolite composition described by Saric et al. (2008)94, the authors 
concluded that a Wf:Vb of 1:2 was optimal. They also investigated the effects of freeze-thaw and 
sonication on subsequent metabolite profiles and found them to have a relatively minor effect on 
metabolite resonance signal-to-noise. Lyophilisation of faecal samples is commonly included as a 
preparative step, to minimise gross concentration differences resulting from contrasting water 
content in samples. It has been noted that some or all volatile compounds will be lost, including 
some considered integral to investigations of the diet, gut contents and action of the microbiome, 
such as short chain fatty acids (SCFAs) 92,94 
 
NMR spectroscopy experiments for obtaining metabolic profiles of prepared (homogenised and 
extracted) faecal samples are largely similar to those for urine (as detailed elsewhere in this book) 
and in standard protocols95, although the influence of extreme dilution (either global dilution in the 
original sample) or in the preparative steps may require additional acquisition time to compensate 
for low metabolite concentrations (or pretreatment by lyophilisation as described above). As 
illustrated by the work of Wu et al. (2010), around 40 abundant metabolites can be readily 
assigned in typical 1H NMR spectra of faecal extracts (Fig. 13.6), including amino acids, SCFAs, 
and bile acids. Jacobs et al. (2008) assessed 1H NMR spectroscopy as an analytical platform for 
faeces metabolome profiling, with a focus on the effect of nutritional interventions (grape juice and 
wine consumption) on the gut microbial composition96 and more recently, Bjerrum et at. (2015) 
investigated metabolite profiles of patients with chronic inflammatory bowel conditions (ulcerative 
colitis and Crohn’s disease), compared to healthy controls.97 In this latter study, the authors 
generated 1H 1D CMPG spectra for stool samples collected from 113 individuals (48 ulcerative 
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colitis, 44 Crohn’s disease, 21 healthy controls) and produced multivariate statistical models based 
on these. They noted the strong influence of surgical procedures and medicinal treatments. The 
use of metabolomics to interrogate the influence of the microbiota on health has been reviewed by 
Martin et al. (2012). 98 
 
[Figure 13.6 near here] 
 
13.4.3  Cerebrospinal Fluid 
Cerebrospinal fluid (CSF) is found in the subarachnoid space and ventricular system in and around 
the brain and spinal cord. It facilitates essential physical, chemical, and immunological functions, 
including protection from mechanical injury, maintenance of homeostasis, and as a route for 
exchange of substrates and waste products of brain biochemical processes. CSF is produced by 
structures in the brain (predominantly the choroid plexuses), and the volume experiences continual 
turnover (approximately every six hours, totalling a production of 400-600mL per day).99 CSF is 
commonly sampled in a clinical context by lumbar puncture for diagnosis of neurological 
abnormalities, detection of infection, and determination of intercranial pressure.100  Sweatman et al. 
(1993) conducted the first major high-field 1H NMR-based study of CSF small molecule 
composition, using a variety of one- and two-dimensional experiments.101 They successfully 
identified and assigned a total of 46 metabolites of endogenous origin. The authors also explored 
the use of lyophilisation and reconstitution of CSF, reporting an improvement in spectral 
characteristics, alongside the expected loss of volatiles such as acetone.  Wevers et al. (1995) 
subsequently reported a standardised method of analysis and indicated the utility of CSF metabolic 
profiling as a diagnostic tool through the characterisation of clinical samples obtained from 
individuals with inborn errors of metabolism.102 The authors reported that, as with other biofluids, 
the pH of the prepared NMR sample was important to ensure good concordance of NMR 
spectroscopic resonances; sample pH has been highlighted as a potential factor in the 
misinterpretation of metabolic profile data (and related chemometric models) by Cruz et al. 
(2014)103, who reviewed the work of Kork et al. (2009, 2012)104,105 and questioned the validity of the 
assignments made / models generated for classification of Alzheimer’s disease patients and 
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severity on account of the substantial pH-dependent shifts observed for the resonances.  Further 
assignment of resonances in 1H NMR spectra of cerebrospinal fluid (CSF) was conducted by Lutz 
et al. (1998) and increased the tally of routinely assignable metabolites considerably, with a 1D 1H 
NMR database created containing the assignments of ~150 metabolites.106  To date, the Wishart 
research group have recently published the most comprehensive CSF analysis – using multiple 
analytical platforms including NMR - and database of CSF metabolome components is now 
available as a community resource (www.csfmetabolome.ca).107,108  
 
Levine et al. (2000) explored the effect of sample handling as a preanalytical factor, comparing 
CSF before and after 72 hrs at room temperature.109 They found significant changes in citrate, 
lactate, glutamine, creatine and creatinine resulted from this prolonged bench residence time, 
highlighting the need to ensure timely analysis to obtain more representative NMR spectroscopic 
profile data. A more extensive optimisation of sample pre-treatment was conducted by Paskevich 
et al. (2013), who determined that the optimal preparation of CSF used buffered, deuterated 
media.110 One major consideration in the preparation and analysis of CSF by NMR spectroscopy is 
sample volume; while it is possible to obtain CSF samples from humans in the milliliter range, 
other species may yield far less (e.g. rats and mice can be sampled in the low microliter range). 
Consequently, NMR spectroscopic analyses may be tailored to accommodate a smaller prepared 
sample volume using narrow-bore students (e.g. <3mm diameter tubes and probes).  CSF is 
naturally well buffered at pH 7.3, but to prevent minor differences in pH having a deleterious effect 
on efficient spectral alignment, preparation of CSF typically includes the addition of a buffer 
solution.108,111 NMR spectral acquisition typically employs the same one-dimensional, spin-echo, 
and J-resolved pulse sequences as used for other biofluids; presaturation of the water resonance 
is required.  The physiological role of CSF obviously makes it a candidate reporter for metabolic 
events related to brain and nervous system function, and this is born out in the dominance of 
publications relating to neurodegeneration, including multiple sclerosis112  (reviewed by Lutz and 
Cozzonne, (2011))113, cervical myelopathy and lumbar radiculopathy114 and use of NMR 
spectroscopic profiles for neurological disease diagnosis. 115 and effect of interventions.116 NMR-
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Breast milk is a complex, water-based colloidal emulsion (a liquid phase dispersed in another liquid 
phase) produced by mammary glands. Dissolved in the colloid are numerous small molecule 
metabolites, proteins, minerals, salts and antibodies that provide a key source of nutrition and 
immunological protection for mammalian neonates. After weaning, humans commonly consume 
animal milk (whole and in preparations) throughout life as part of the everyday diet. Despite the 
widespread consumption of milk, relatively few studies have investigated the metabolic 
composition and/or dynamism of human breast milk using NMR spectroscopy. An overview of the 
state of development of NMR-based metabolomics of milk has previously been published.119 As a 
complex colloid, milk places additional demands on the NMR sample preparation; one key 
consideration is the removal of casein micelles (phosphoproteins that comprise a large percentage 
of total milk protein) by precipitation or centrifugation to limit their influence on the small molecule 
NMR spectral profile, and as expected, CPMG acquisitions are preferred to suppress broad signals 
in most studies. Quantitatively, lactose is the most abundant metabolite, with other major 
components including galactose and citrate. Other individual metabolites are typically one or more 
order of magnitude lower in abundance. The first published example was conducted by Cesare-
Marincola and co-workers, who used NMR spectroscopy in conjunction with GC-MS in a 
comparative metabonomics analysis of human breast milk and formula milk.120 Given the volume 
of animal milk consumed, animal studies have sought to investigate biological markers relating to 
both quality of the milk and also the health status of the animal; for example, Sundekilde et al. 
(2011, 2013) identified metabolic profile features correlated with both breed and somatic cell count 
in bovine milk. 121,122 There is considerable interest in developing optimised metabolic profiling 
methods for human milk, particularly in relation to understanding neonate/child nutrition and health. 
120,123-125 Wu et al. (2016) recently used NMR spectroscopic analysis to explore milk metabolome 
compositional changes during stages of lactation (early 9-24 days after delivery vs late 31-87 
days); surveying a set of 36 metabolites, the authors noted that milk samples obtained in later 
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stages contained elevated lactose, choline and changes in the amino acid profile, alongside 
decreases in PC and GPC components. 126 The ability to rapidly collect, analyse and report 
metabolic composition by NMR spectroscopy in this way potentiates the ability to more closely 
monitor infant nutrition and augment other measures in neonatal care. In additional to evaluating 
the effects of relative storage temperature (-20 C vs -80 C) for various periods (up to seven days), 
these authors also compared methanolic precipitation with ultrafiltration, with the latter reported to 
more optimally remove lipid and proteins. Key metabonomics studies of milk are shown in Table 
13.1. 
 
[Table 13.1 near here] 
Requires references: 120,125,127 128 
 
13.4.5  Seminal Fluid 
Semen is a complex biofluid originating in the male gonads, containing seminal fluid (SF) plasma 
(collectively produced by the seminal vesicle, prostate gland, the bulbourethral glands, and other 
minor accessory structures) and spermatozoa (produced in the testes).  The SF provides a 
protective medium in which spermatozoa can survive, containing an abundance of available 
sugars (particularly fructose) that meet the high energy requirements of these motile cells, and 
polyamines (e.g. spermine, spermidine) and citrate that afford a capacity to buffer pH and 
inorganic ion concentrations, respectively. In addition to those of low-molecular-weight, other SF 
components modulate the physical and chemical properties of semen, and include mucus, 
proteins, and proteolytic enzymes (including prostate-specific antigen, PSA; responsible for the 
liquefaction of coagulated semen). 
 
The simplest preparation of seminal plasma from semen samples is centrifugation to remove 
cellular material. In this case, there is requirement to wait until liquefaction has occurred (~20 
minutes at RT post-ejaculation), resulting from the action of PSA. Dilution with D2O containing a 
NMR chemical shift reference compound (e.g. TSP-d4) has been used to reduce viscosity129 for an 
efficient sample preparation (can easily be combined with an additional lyophilisation step).  
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Tomlins et al. (1998) investigated pre-analytical / preparative aspects in detail using human semen 
samples, and described the time-related changes that occur in SF that could be observed by 1H 
NMR at a field strength of 14.1 Tesla. Conversion of phosphorylcholine to choline, and uridine-5’-
monophosphate to uridine were the main observable changes occurring in the experimental 
timescale (sampled between 2 min and 3 hr post-ejaculation).  The authors also investigated the 
effect of immediate incubation of semen samples with the chelating agent 
ethylenediaminetetraacetic acid (EDTA), showing an inhibition of peptide hydrolysis by SF 
metalloenzymes, evidenced by the constancy of amino acid resonances up to 24 hrs after addition. 
Resonances characteristic of complexes of EDTA with Ca2+, Zn2+ and Mg2+ were observed, and 
their formation concomitant with reduced chelation by citrate. Lynch and coworkers (1994) 
subsequently investigated individually seminal fluid (SF, allowed to liquefy for 30 min post 
ejaculation), and its main component fluids: prostatic fluid (PF, collected by prostatic massage), 
and seminal vesicle fluid (SVF, collected during surgery). 129 The authors report that NMR spectra 
of prostatic fluid have very large contributions from citrate, spermine and myo-inositol, in contrast 
to SVF where GC and lactate are major contributors. These authors investigated the effect of vasal 
aplasia (occlusion of the vas deferens) on the fluid profiles, which were highly characteristic of the 
limited SVF contribution in these samples versus unaffected control. Given the direct interaction 
and role of semen in the male reproductive system, analyses of the component fluids have largely 
been focused on their application to fertility and chronic disease of the reproductive organs. For 
example, Hamamah et al. (1998) explored the differences in seminal metabolite profiles in relation 
to azoospermia arising from various conditions, reporting that key profile discriminants related to 
specific ratios of glycerol-phosphatidylcholine, choline, citrate and lactate, and suggesting a path 
towards more tailored interventions relating to male infertility that minimise invasive procedures. 130 
More recently, Bonechi et al. (2015) conducted an analysis of human semen, and generated 
multivariate statistical models that could discriminate samples based on a number of sperm quality 
metrics, and also identified atypical samples as outliers suggesting a more role for such analyses 
in clinical fertility care. 131 Averna et al. (2005)132 conducted a 1H NMR spectroscopic investigation 
semen metabolic profiles in relation to of prostate cancer status (on account of the high proportion 
of prostatic fluid in overall semen content), reporting significant decreases in citrate concentrations 
 
- 25 - 
associated with tumorigenesis, and highlighting how NMR spectroscopy could facilitate rapid 
screening in this context. 
 
13.4.6  Bile 
Bile is continuously produced in the liver, temporarily stored in the gallbladder, and subsequently 
secreted into the upper small intestine (duodenum) in response to consumption of foodstuffs; bile 
contains amphipathic bile salts that help emulsify lipids in the gut contents to form droplets known 
as micelles, a process that greatly increases the available surface area that can be accessed by 
lipases. Biliary excretion is an important route for the efflux of higher molecular weight metabolites, 
such as xenobiotic conjugates. As a consequence, the metabolite profile of bile reports on specific 
aspects of liver function, and can also indicate how exogenous compounds are handled by the 
body. Although relatively plentiful, bile presents a particularly challenging biofluid to obtain, handle 
and use in the context of metabolome studies. In addition to the difficulty of collection (c.f. urine, 
plasma), one issue that affects NMR analyses in particular is the emulsifying properties of bile and 
the formation of micelles. The affinity of lipophilic compounds for the lipid core of the micelles 
means they become compartmentalised and result in very broad resonance in NMR spectra. 
Accordingly, depending on the focus on the analysis, preparation of bile for analysis by NMR may 
involve a simple dilute-and-shoot approach of the whole bile, or a more involved extraction 
procedure to preselect and/or concentrate specific metabolite classes to aid detection, permit 
resolution from other bile components, and eliminate/limit the effect of micelles in the sample. Bile 
can be obtained from the liver or gallbladder, each of which have a distinct but largely similar 
composition from the perspective of sample preparation and NMR analysis. 
 
The first NMR analysis of hepatic bile at 18.8 T was conducted by Duarte et al. (2009). Example 
spectra are shown in Figure. 13.7. These authors were the first to characterise hepatic bile, and 
incorporated 800MHz 1H NMR spectroscopy into a multi-platform analytical setup. 133 Using two-
dimensional 1H-1H TOCSY and 1H-13C HSQC spectra, the authors were able to positively assign 
40 compounds in spectra obtained from a whole bile sample (see Fig 13.8).  
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[Figure 13.7 near here] 
 
[Figure 13.8 near here] 
 
Metabolites identified included amino acids, organic acids, carbohydrates (including glucose, 
glycerol and myo-inositol), alongside choline and several related quaternary ammonium 
compounds (including phosphocholine, phosphatidylcholine, betaine, trimethylamine-N-oxide). It 
was noted that the observed chemical shifts differed from value available in community databases, 
attributed to differences in the bulk diamagnetic susceptibility in this biofluid. In addition to high 
abundance bile acids, the authors noted that the related glycine and taurine conjugates of these 
major bile acid metabolites could not be adequately resolved to allow positive identification. To 
date, multiple NMR- spectroscopic studies have been conducted to characterise bile 
composition134-137 with applications focused on characterising biliary and hepatic diseases and 
pancreatic cancer138; reviewed by 139 For example, Gowda et al. (2009) used 1H NMR profiling of 
bile obtained from the gallbladder of 44 individuals with a range of liver pathologies (17 controls, 11 
hepatcellularcarcinoma (HCC), 7 cholangiocarcinoma, 9 non-malignant liver disease). 140 The 
authors prepared bile samples in both aqueous media (dilution with H2O/D2O) and non-aqueous 
media (DMSO) prior to analysis. They found significant changes in the bile acid profile - notably the 
ratio between major glycine- and taurine- conjugated bile acids were decreased in the non-
malignant group, relative to control. HCC samples could also be differentiated from the non-
malignant group based on the concentration of glycine-conjugated bile acids. 
 
13.4.7  Less Commonly Reported Biofluids 
As above, most biofluids that can be sampled have the potential to provide highly specific 
information about system, organ, and cellular function. Many are not routinely collected, but can be 
useful in relation to the diagnosis of particular pathologies, and NMR-based metabolome analysis 
offers a useful window to capture the small-molecule component of such investigations; NMR-
based metabolomics has been used to diagnostic fluids such as amniotic fluid141, 
 
- 27 - 
tears/meibomian142, synovial fluid143,144, cervical mucus114, and pathological fluids such as 
ascites145 among many others. 
 
13.5  Summary and Future Developments 
While the influence on the various physicochemical (e.g. time, temperature, mechanics) and 
biochemical (e.g. enzymatic action, sequestration) aspects of these procedures continue to provide 
researchers with an ongoing challenge to best extract metabolites across many chemical classes, 
the general workflows appear largely established. Converging on the ability to generate soluble 
fractions of the original sample that are free from confounding matrix, and prepared in a way so as 
to minimise the effects of sampling/handling on resultant metabolic profile data, predominantly 
one-dimensional 1H NMR experiments can provide spectra that faithfully represent the small 
molecular composition at the time and site of sampling.  Partly due to the lack of effective 
quenching and separation procedure, but mainly due to low sensitivity, the role of NMR 
spectroscopy for intracellular metabolite profiling has declined in recent years.  However, for some 
applications that require detection of high concentration metabolites of different chemical classes 
such as osmolytes or storage metabolites, NMR remains a powerful and useful analytical platform, 
especially if concomitant structural elucidation is important.146 Coupled with advances in the 
sensitivity of instrumentation/analyses (high field strengths, cryoprobe technology, improved pulse 
sequences), and more routine use of techniques such as DNP147 and stable isotope labelling148,149, 
it is likely that NMR will remain in the toolkit for metabolic profiling of cellular materials for the 
foreseeable future.  
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